Pressmeddelanden, rapporter och bolagsmeddelande för Optomed Oyj

Optomed Plc reported a manager's transaction on August 9, 2024, involving Ty Lee, a member of the Board. Lee received a share-based incentive consisting of 1,249 shares, with no associated cost. The transaction was classified as an initial notification.

On August 9, 2024, at 18:30 EET, Optomed Plc reported a manager's transaction involving Petri Salonen, a member of the Board/Deputy member. The transaction, which was an initial notification, involved the receipt of a share-based incentive. The transaction date was August 9, 2024, and the instrument type was a share with ISIN FI4000410881. The transaction involved 2499 shares at a unit price of 0.00 EUR, resulting in a volume-weighted average price of 0.00 EUR.

Optomed Plc reported a manager's transaction involving Laura Piila, a senior manager. The initial notification states that on August 7, 2024, Piila subscribed to 28,000 shares at a unit price of 3.50 EUR, linked to a stock option program. The aggregated transaction volume was 28,000 shares with a volume-weighted average price of 3.50 EUR.

Optomed Plc reported a manager's transaction involving Anna Tenstam, a member of the Board, on August 9, 2024. Tenstam received 1,249 shares as a share-based incentive, with a unit price of 0.00 EUR. The transaction is categorized as an initial notification.

Optomed Plc reported a manager's transaction involving Catherine Calarco, a member of the Board, on August 9, 2024. Calarco received 1,249 shares as a share-based incentive. The transaction had no unit price, resulting in a volume-weighted average price of 0.00 EUR.

Optomed Plc reported a manager's transaction on August 9, 2024, involving Reijo Tauriainen, a member of the board. The transaction, identified by reference number 7437009IVYWGEE4S7B77_20240809145959_58, involved the receipt of a share-based incentive. On the transaction date, 1249 shares with ISIN FI4000410881 were received, with a unit price of 0.00 EUR. The volume-weighted average price for the aggregated transactions was also 0.00 EUR.

Optomed Plc announced its financial reporting schedule for 2025. The Annual Report for 2024, including financial statements, the Board of Directors' report, corporate governance statement, and remuneration report, will be published by the week starting 24 February 2025. The Annual General Meeting is planned for 9 May 2025 in the Helsinki region, with the Board of Directors to convene the meeting later. Shareholders wishing to add items to the meeting agenda must notify the Board in writing by 13 March 2025. Optomed is a Finnish medical technology company specializing in handheld fundus cameras and software for diagnosing eye diseases, with operations in over 60 countries and 55 international patents. For further information, contact CFO Sakari Knuutti.

Optomed Plc released its financial results for Q2 2024, showing a decline in revenue by 6.4% to EUR 3.5 million compared to the same period last year. The Devices segment saw a 15.7% revenue decrease, while the Software segment's revenue decreased by 1.6%. The gross margin improved to 69.9% from 66.4%. Adjusted EBITDA was EUR -0.8 million, and EBIT was EUR -1.9 million. Net profit/loss for the period was EUR -1.8 million, with earnings per share at EUR -0.10. Cash flow from operating activities was EUR -560 thousand. Optomed completed a directed share issue raising EUR 7.9 million, resulting in cash and cash equivalents of EUR 12.1 million at the end of the period. The company received FDA clearance for its Optomed Aurora with AEYE-DS AI, the first handheld device with autonomous AI for diagnosing diabetic retinopathy. Additionally, Optomed entered a joint venture in China with Zhongbao, owning 19.9% of the venture. For H1 2024, revenue decreased by 5.4% to EUR 6.8 million, with the Devices segment down by 9.2% and the Software segment by 3.8%. The gross margin slightly decreased to 68.2%. Adjusted EBITDA was EUR -1.5 million, and EBIT was EUR -3.1 million. The Annual General Meeting held on May 10, 2024, resolved that no dividend would be paid for 2023. Optomed's Board of Directors was re-elected, and KPMG Oy Ab was re-elected as the company's auditor. The company remains optimistic about its growth prospects for 2024 and continues to invest in product development and market expansion. A telephone conference for analysts, investors, and media will be held on August 8, 2024.